License was Abeona Therapeutics’s largest product and service line in fiscal 2025, bringing in $6.00M of $10.84M (55%).
| Product and Service | FY 2011 | FY 2011 | FY 2011 | FY 2011 | FY 2012 | FY 2012 | FY 2012 | FY 2013 | FY 2013 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2020 | FY 2021 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $7.00M | $6.00M | ||||||||||||||||||||
| License Revenues | — | — | ||||||||||||||||||||
| Foundation Revenues | — | — | ||||||||||||||||||||
| Product | — | $4.84M | ||||||||||||||||||||
| Mugard | — | — | ||||||||||||||||||||
| License Revenues[Member] | — | — | ||||||||||||||||||||
| Royalties | — | — | ||||||||||||||||||||
| Total | $7.00M | $10.84M |
Abeona Therapeutics brought in $10.84M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Abeona Therapeutics regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $7.00M. License was the largest at $6.00M (55.4%), ahead of Product at $4.84M (44.6%).
Abeona Therapeutics began breaking out Product in fiscal 2025, when it brought in $4.84M.
Effect Of Asc 606 was Abeona Therapeutics’s largest revenue line in fiscal 2018, bringing in $3.18M of $6.00M (53%).
| Restatement | FY 2018 |
|---|---|
| Effect Of Asc 606 | $3.18M |
| Under Asc 605 | $2.81M |
| Total | $6.00M |
Abeona Therapeutics brought in $6.00M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Effect Of Asc 606 was the largest at $3.18M (53.1%), ahead of Under Asc 605 at $2.81M (46.9%).
Abeona Therapeutics (ABEO) reports its revenue by product and service and by restatement. In fiscal 2025, License was its largest product and service line, bringing in $6.00M (55.4% of the total), followed by Product at $4.84M (44.6%).
License was Abeona Therapeutics' largest product and service line in fiscal 2025, bringing in $6.00M, or 55.4% of the $10.84M total across its two product and service lines.
Effect Of Asc 606 was Abeona Therapeutics' largest revenue line in fiscal 2018, bringing in $3.18M, or 53.1% of the $6.00M total across its two revenue lines.
Every figure comes from Abeona Therapeutics' annual financial filings, as reported. Each line keeps the name Abeona Therapeutics gives it, and years follow its fiscal calendar.
Abeona Therapeutics' revenue by product and service goes back to fiscal 2011, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.